Join to View Full Profile
200 South Manchester Ave, Suite 400Orange, CA 92868
Phone+1 714-456-5153
Dr. Ou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
Duke University HospitalResidency, Internal Medicine, 1997 - 2000
University of Texas Southwestern Medical SchoolClass of 1997
Certifications & Licensure
CA State Medical License 2003 - 2027
AZ State Medical License 2008 - 2025
NC State Medical License 1999 - 2025
TX State Medical License 2010 - 2024
MA State Medical License 2000 - 2017
Clinical Trials
- Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Roles: Contact
Publications & Presentations
PubMed
- Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, Alessandra Bearz, Chia-Chi Lin
Journal of Thoracic Oncology. 2025-04-01 - Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2025-04-01 - Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.Sarah Waliany, Yin P Hung, Fawzi Abu Rous, Faustine Luo, Marzia Capelletti
Clinical Lung Cancer. 2025-03-25
Lectures
- Liquid Biopsy to Identify Actionable Genomic Alterations2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- Medical Oncologist’s Perspective2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).2018 ASCO Annual Meeting - Chicago, Illinois - Chicago, Illinois- Chicago, Illinois - 06/3/2018
- Join now to see all
Press Mentions
Oncologist’s Insider Trading Case Highlights Widespread Risk for DoctorsJanuary 31st, 2025- Alectinib Shows Promise in Crizotinib-Refractory ALK-Rearranged NSCLCNovember 23rd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
